← Issue №8/ week of Aug 23, 2026/Motility

Magnetic Resonance Defecography Criteria for the Diagnosis of Dyssynergic Defecation.

From GI Signals issue №8: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Motility retrospective · n=109 · Aug 19, 2026 · J Neurogastro Motil · IF 3.4

Magnetic Resonance Defecography Criteria for the Diagnosis of Dyssynergic Defecation.

Diagnosticchronic constipationanorectal manometrybiomarker
Clinical takeawayIn chronic constipation patients suspected of dyssynergic defecation who cannot or decline HR-ARM, MRD may provide a non-invasive diagnostic alternative with moderate-to-good diagnostic odds ratios (8.25-14.25). Requires prospective external validation and clarification of specific diagnostic thresholds and their directional criteria before adoption as primary diagnostic criteria.
What it foundSpecific quantitative MRD parameters, M-line measurement, anorectal angle (ARA), and anal canal width (ACW), with emphasis on puborectalis muscle prominence or abnormal evacuation assessment, demonstrated discriminatory ability for dyssynergic defecation. Numeric cutoff thresholds (M-line 2.0 cm, ARA 114°, ACW 10 mm) achieved specificities of 82.1-92.3%, positive likelihood ratios of 3.66-7.06, and diagnostic odds ratios of 8.25-14.25; ARA and ACW at defecation were identified as independent predictors. Direction of cutoff relationship to dyssynergic diagnosis specified in source.
ContextDyssynergic defecation is currently diagnosed via high-resolution anorectal manometry combined with functional testing (balloon expulsion). MR defecography is non-invasive dynamic imaging of pelvic floor mechanics during defecation. Prior evidence for MRD diagnostic criteria in dyssynergic defecation is limited. This retrospective study establishes specific MRD measurement thresholds that discriminate dyssynergic defecation from normal, potentially providing an imaging-based diagnostic alternative for patients who cannot or refuse manometry.
Measured against the standard of care· AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993)

Decision at stakehow to diagnose dyssynergic defecation in patients presenting with constipation, to determine appropriate management pathway

First-line drug treatment for adults with chronic idiopathic constipation has not changed. … For obstructed defecation and posterior compartment or rectal prolapse, a 2026 consensus of the ASCRS Pelvic Floor Consortium with ICS, IUGA, AUGS and APTA (15 statements, >70% consensus, expert-consensus evidence) advises prompt referral to pelvic floor physical therapy for patients without contraindications. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

First-line drug treatment for adults with chronic idiopathic constipation has not changed. It still follows the AGA-ACG 2023 GRADE guideline. STRONG recommendation (moderate certainty) for polyethylene glycol. STRONG recommendation (moderate certainty) for bisacodyl or sodium picosulfate, limited to short-term or rescue use. CONDITIONAL suggestion for fiber (low certainty), magnesium oxide (very low) and senna (low). For patients who do not respond to, fail, or cannot tolerate over-the-counter agents: STRONG recommendation (moderate certainty) for linaclotide, plecanatide and prucalopride, and CONDITIONAL suggestion for lubiprostone (low) and lactulose (very low). The guideline gives no doses, no required order and no fixed trial length; it uses shared decision making and leaves anorectal evacuation disorders to the ACG 2021 benign anorectal guideline. Added on top of this is the AGA 2026 Clinical Practice Update on refractory constipation (Staller, Neshatian, Lembo, Bharucha; expert-opinion Best Practice Advice, 14 key clinical issues, no formal evidence grading). Before calling constipation refractory, clinicians should systematically (1) exclude correctable secondary causes: medications, neurologic disorders, and defecatory disorders; (2) confirm slow colonic transit objectively, ideally both off therapy and on maximal therapy; and (3) make sure the patient has had adequate trials of over-the-counter and FDA-approved drugs and nonpharmacologic therapy, including combinations. Most patients should have anorectal testing and, when indicated, pelvic floor biofeedback before being labeled refractory. Colectomy can be considered only after all of these fail. Before surgery: confirm slow transit, exclude a concurrent defecatory disorder, evaluate for severe symptomatic delayed gastric emptying or small-bowel dysmotility, and do a psychological evaluation. Relative contraindications are clinically significant upper-gut dysmotility, severe untreated psychiatric disease, and bloating or abdominal pain as the main complaint. A temporary diverting loop ileostomy may predict response in uncertain cases. Colectomy with ileorectal anastomosis should be offered only to patients without an ongoing defecatory disorder. For obstructed defecation and posterior compartment or rectal prolapse, a 2026 consensus of the ASCRS Pelvic Floor Consortium with ICS, IUGA, AUGS and APTA (15 statements, >70% consensus, expert-consensus evidence) advises prompt referral to pelvic floor physical therapy for patients without contraindications. It also advises therapy individualized to the diagnostic evaluation and the patient's goals, deliberate timing of therapy relative to surgery, and trauma-informed care.

AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993) · reviewed 2026-10-25 ↗
Keeratichananont S … Netinatsunton N · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
← Read the whole of issue №8 Every paper GI Signals surfaces gets a page like this one. All issues